Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
LeMaitre Vascular (NASDAQ:LMAT - Get Rating) was upgraded by investment analysts at StockNews.com from a "hold" rating to a "buy" rating in a report released on Wednesday.LeMaitre Vascular Price Performance
NASDAQ:LMAT traded down $0.99 during mid-day trading on Wednesday, reaching $51.26. The stock had a trading volume of 118,550 shares, compared to its average volume of 108,625. The business's 50 day moving average is $51.21 and its 200 day moving average is $47.30. LeMaitre Vascular has a fifty-two week low of $38.32 and a fifty-two week high of $56.47. The stock has a market cap of $1.13 billion, a P/E ratio of 50.75, a PEG ratio of 4.41 and a beta of 1.11.
LeMaitre Vascular (NASDAQ:LMAT - Get Rating) last released its quarterly earnings data on Thursday, July 28th. The medical instruments supplier reported $0.29 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.03). The firm had revenue of $42.11 million during the quarter, compared to analyst estimates of $41.26 million. LeMaitre Vascular had a return on equity of 9.86% and a net margin of 13.94%. Equities analysts expect that LeMaitre Vascular will post 1.16 EPS for the current year. Insiders Place Their Bets
In other LeMaitre Vascular news, CFO Joseph P. Pellegrino, Jr. sold 18,693 shares of the company's stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $53.99, for a total transaction of $1,009,235.07. Following the completion of the sale, the chief financial officer now owns 6,108 shares of the company's stock, valued at $329,770.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Joseph P. Pellegrino, Jr. sold 18,693 shares of the stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $53.99, for a total value of $1,009,235.07. Following the completion of the sale, the chief financial officer now directly owns 6,108 shares of the company's stock, valued at $329,770.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO George W. Lemaitre sold 6,890 shares of the stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $52.67, for a total value of $362,896.30. Following the completion of the sale, the chief executive officer now directly owns 2,480,908 shares of the company's stock, valued at $130,669,424.36. The disclosure for this sale can be found here. Insiders sold 64,633 shares of company stock valued at $3,534,996 over the last 90 days. 12.50% of the stock is currently owned by company insiders. Institutional Investors Weigh In On LeMaitre Vascular
Several hedge funds have recently modified their holdings of the business. Captrust Financial Advisors lifted its position in LeMaitre Vascular by 555.3% in the first quarter. Captrust Financial Advisors now owns 616 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 522 shares during the period. FinTrust Capital Advisors LLC bought a new position in LeMaitre Vascular in the second quarter worth $76,000. Hardy Reed LLC bought a new position in LeMaitre Vascular in the first quarter worth $91,000. Lazard Asset Management LLC lifted its position in LeMaitre Vascular by 48.8% in the second quarter. Lazard Asset Management LLC now owns 2,563 shares of the medical instruments supplier's stock worth $116,000 after purchasing an additional 841 shares during the period. Finally, First Horizon Advisors Inc. lifted its position in LeMaitre Vascular by 2,150.4% in the second quarter. First Horizon Advisors Inc. now owns 2,678 shares of the medical instruments supplier's stock worth $122,000 after purchasing an additional 2,559 shares during the period. 88.45% of the stock is owned by institutional investors. LeMaitre Vascular Company Profile (Get Rating)
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.Featured ArticlesGet a free copy of the StockNews.com research report on LeMaitre Vascular (LMAT)Hot Potato: Lamb Weston Stock Confirms a Top Too Soon: 3 Reasons to Wait on DocuSign StockRite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear Don't Give Up on These Q3 LosersVertex Shares Higher On Optimism About CRISPR Partnership
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LeMaitre Vascular, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.
While LeMaitre Vascular currently has a "N/A" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:
Kirk McDonald shares three stocks from different industries with different market caps and explains why each is a holding in his portfolio.
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.